71.64
1.67 (2.39%)
| Penutupan Terdahulu | 69.97 |
| Buka | 69.25 |
| Jumlah Dagangan | 593,311 |
| Purata Dagangan (3B) | 564,530 |
| Modal Pasaran | 5,129,273,856 |
| Harga / Buku (P/B) | 4.44 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.93 |
| Nisbah Semasa (MRQ) | 20.96 |
| Aliran Tunai Operasi (OCF TTM) | -185.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -100.02 M |
| Pulangan Atas Aset (ROA TTM) | -18.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Nuvalent, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -1.0 |
| Purata | 0.50 |
|
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.90% |
| % Dimiliki oleh Institusi | 108.05% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Commodore Capital Lp | 31 Dec 2024 | 1,621,600 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (HC Wainwright & Co., 53.55%) | Beli |
| Median | 105.00 (46.57%) | |
| Rendah | 100.00 (UBS, 39.59%) | Beli |
| Purata | 105.00 (46.57%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 74.02 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 14 Mar 2025 | 100.00 (39.59%) | Beli | 77.01 |
| HC Wainwright & Co. | 03 Mar 2025 | 110.00 (53.55%) | Beli | 71.03 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |